Palm-Sized Device Quickly Detects Ebola Virus
By LabMedica International staff writers Posted on 18 May 2016 |
Image: The handheld device that can detect Ebola Virus Ribonucleic Acid (Photo courtesy of KIST Europe).
The gold standard method for identifying the Ebola virus in a blood sample requires packaging samples in cooled containers and sending them to specialized laboratories, often far away from where patients live.
These laboratories use a method called reverse-transcription polymerase chain reaction, or RT-PCR, to check for the virus. The prolonged testing process delays detection, treatment and real-time monitoring of viral loads in body fluids that can harbor the virus even after it is no longer detected in the blood.
Scientists at the Korea Institute of Science and Technology Europe (KIST, Saarbrücken, Germany) and their colleagues have designed and tested an instrument, which could simultaneously perform four RT-PCRs that included two controls and two patient blood samples. Conventional tests require several hours to more than a day for results to come in. The new process was completed in slightly over 30 minutes. The amount of blood required was 100 nL and could potentially come from just a finger prick.
The device was shown to concurrently perform four PCRs, one positive control with both Ebola and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA and one negative control. The device successfully detected the Ebola ribonucleic acid (RNA). In addition to diagnosing the illness, the test also yielded information about how many RNA copies each sample contained. In addition to diagnosing the illness, the experts say that the tool could also potentially help health care workers track patients' viral loads in semen, breast milk and eye fluids after recovery.
A comparison of threshold cycles (CT) from the two samples provided relative quantification. The entire process, which consisted of reverse transcription, PCR amplification, and melting curve analysis (MCA), was conducted in less than 37 min. The next step will be integration with a sample preparation unit to form an integrated sample-to-answer system for point-of-care infectious disease diagnostics. The study was published on April 11, 2016, in the journal Analytical Chemistry.
Related Links:
Korea Institute of Science and Technology Europe
These laboratories use a method called reverse-transcription polymerase chain reaction, or RT-PCR, to check for the virus. The prolonged testing process delays detection, treatment and real-time monitoring of viral loads in body fluids that can harbor the virus even after it is no longer detected in the blood.
Scientists at the Korea Institute of Science and Technology Europe (KIST, Saarbrücken, Germany) and their colleagues have designed and tested an instrument, which could simultaneously perform four RT-PCRs that included two controls and two patient blood samples. Conventional tests require several hours to more than a day for results to come in. The new process was completed in slightly over 30 minutes. The amount of blood required was 100 nL and could potentially come from just a finger prick.
The device was shown to concurrently perform four PCRs, one positive control with both Ebola and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA and one negative control. The device successfully detected the Ebola ribonucleic acid (RNA). In addition to diagnosing the illness, the test also yielded information about how many RNA copies each sample contained. In addition to diagnosing the illness, the experts say that the tool could also potentially help health care workers track patients' viral loads in semen, breast milk and eye fluids after recovery.
A comparison of threshold cycles (CT) from the two samples provided relative quantification. The entire process, which consisted of reverse transcription, PCR amplification, and melting curve analysis (MCA), was conducted in less than 37 min. The next step will be integration with a sample preparation unit to form an integrated sample-to-answer system for point-of-care infectious disease diagnostics. The study was published on April 11, 2016, in the journal Analytical Chemistry.
Related Links:
Korea Institute of Science and Technology Europe
Latest Molecular Diagnostics News
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing